as native SK. PEG-lZ61-SK cleared slowly (tlI2 greater than 200 minutes), with more than 80% of the preparation localizing in liver and GI tract. The PEG-'261-SK secreted into the bile was also intact. The bile containing 1261-SK was TREPTOKINASE (SK), a widely used thrombolytic S drug, is a well-characterized bacterial protein that forms high affinity stoichiometric complexes with human plasminogen (Pg).' On complex formation with SK, a change in conformation within the molecule results in active site specificity distinct from that of plasmin.* The Pg originally present in the complex is itself rapidly converted to p l a~m i n .~.~ The SK-plasmin activator complex (SK:Pm) cleaves the Arg 560-Val 561 peptide bond of Pg generating plasmh2 Pg activation by SK is species-specific4; eg, murine Pg does not react with SK.5 S K has been used as a fibrinolytic agent for several decades in the treatment of acute myocardial infarction, deep-vein thrombosis, and other thrombosis-related pathogenic states. 6 Some limitations to S K therapy have been imposed by its bacterial origin. SK therapy is occasionally complicated by immune responses from patients possessing moderate to high titers of anti-SK antib~dies.'.~ Polyethylene glycol (PEG) conjugation to proteins substantially alters properties such as half-life, antigenic recognition, and stability.'-" Derivatization of S K by PEG renders SK nonantigenic, extends its half-life in plasma, and protects PEG-SK:Pm complexes from proteolysis. I The clearance mechanisms of SK, PEG-SK, and their respective complexes with Pm are not well-understood, and the fate of S K cleared alone or in complex with Pm has not been investigated in detail. The objectives of this study were to explore the clearance pathway of S K and PEG-SK in detail, characterize their respective Pm complexes, and examine the effect of Pm on SK in vivo.
MATERIALS AND METHODS
Bovine serum albumin, ammediol, and 3,4-dichloroisocoumarin (DCI) were obtained from Sigma Chemical Co (St Louis, MO); l,I'-carbonyldiimidazole and Iodobeads were obtained from PierceCo (Rockford, IL). Nal*'I was purchased from New England Nuclear (Boston, MA). Lactoperoxidase coupled to Sepharose was obtained from P-L Biochemicals, Inc (Milwaukee, WI). The Kabi
ide-2HC1 (S-2251) was used as the plasmin substrate and obtained
Reagents.
incubated with stoichiometric amounts of plasminogen and electrophoresed under nondenaturing conditions. This study demonstrated that the secreted SK was able t o form SK:Pg complexes. SDS-PAGE also showed activation of 1261-Pg that was incubated with recovered bile containing the SK.
I-SK:Pm catabolism was also studied. In these experiments, the mol w t -42,000 fragment obtained when SK is cleaved by plasmin was found in the bile. Proteins. Pg was purified from human plasma by affinity chromatography on lysine-Sepharose as described by Deutsch and Mertz" and modified by the method of Brockway and Caste1lin0.l~ SK (Kabikinase) was obtained from the Kabi Co, and purified by the method of Brockway and cast ell in^.'^ The homogeneity of the SK was verified by analysis using a mono Q ion exchange column on a Fast Protein Liquid Chromatography Pharmacia System (Pharmacia, LKB, Piscataway, NJ). The column was eluted with a buffer system consisting of Nap,, 50 mmol/L; sodium borate, 10 mmol/L, pH 8.0 (Buffer A), and a limit buffer identical to Buffer A except for Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gradient ammediol gel electrophoresis, 5% to 1575, was performed according to the method of Bury." Proteolytically active samples were incubated with 50 pmol/L DCI and then reduced with 10 mg/mL dithiothreitol (DTT) in SDS sample buffer. Nondenaturing PAGE was also performed. Autoradiographs were made with Kodak XAR-Omat film (Eastman Kodak, Rochester, NY).
Female CD-1 mice were injected intraperitoneally with 50 jtL of 100 mg/mL ketamine, 10 mg/mL acepromazine mixed at a ratio of 2:l for clearance experiments. Radiolabeled proteins were injected into the lateral tail vein of the mice and 25-pL blood samples were obtained from retroorbital venous plexus punctures 5 to 10 seconds after injection and at various intervals. Radiolabeled ligands were injected in the presence of various unlabeled ligands for some of the studies described. Only freshly labeled ligands were used, and the amounts injected ranged from 0.15 to 30 pg. Heparinized capillary tubes used for blood collection were analyzed in a gamma counter. Plasma elimination studies were always performed at least in duplicate (n = 2 to 24).
These studies were performed in duplicate. Blood samples for electrophoresis were collected from retroorbital bleeds in 100-pL heparinized capillary tubes, mixed with 20 pL 3.7% sodium citrate, and centrifuged in a Fisher microfuge at 4°C for 5 minutes. Plasma was reduced in SDS sample buffer and electrophoresed. Organs were recovered at approximately one half-life after cervical dislocation. Organs were placed on ice and each was washed at least three times before radioactivity was determined. Wash buffer consisted of cold 150 mmol/L NaC1, 20 mmol/L Nap,, 10 mmol/L EDTA, pH 7.4. Livers were homogenized in a hand-held glass homogenizer with 10 mL of cold wash buffer. Homogenates were centrifuged at 3,500 rpm at 4°C for 10 minutes. The lipid layer was removed and homogenates were centrifuged at 3,500 rpm and then reduced in SDS sample buffer for SDS-PAGE. Gallbladders were trimmed free of any adhering liver tissue, washed, ruptured, and counted for bile in the gamma counter. The bile volume ranged from 10 to 40 pL. Bile was reduced in SDS sample buffer for electrophoresis. For Pg activation studies by SK recovered from bile, gallbladders were washed with 100 mmol/L Tris-acetate, pH 7.4, and kept on ice.
Competition experiments were performed in duplicate, as were competitions in nephrectomized animals. CD-1 mice were anesthetized with 160-pL intrathigh bolus injection containing 1.6 mg each of ketamine and zylazine." Midline incisions were made into the abdominal cavity when both pedal and eye blink responses were no longer present. The renal vein, artery, and ureter were ligated bilaterally. The abdominal cavity was closed by suturing and the animal was placed on saline-soaked gauze. At the completion of each study along with the other major organs, the kidneys were retrieved, washed, and counted in the gamma counter to verify completeness of the functional nephretomy.
These experiments were performed in triplicate. 1251-SK was recovered from bile after approximately one half-life of plasma elimination. A 1: 1 stoichiometric ratio of IZ5I-SK to unlabeled Pg was calculated based on the recovered Plasma elimination studies.
Organ distribution, tissue, and plasma studies.
Nephrectomy and competition studies.
'z51-SK binding to plasminogen. radioactivity and the known specific radioactivity of the SK preparation. Complexes were then formed at 22OC for I O minutes. Complexes were treated with DCI, placed in native sample buffer, and electrophoresed under nondenaturing conditions on 5% to 15% ammediol gels.
These experiments were performed in triplicate. '251-SK, 25 to 30 pg, was injected into the lateral tail veins of anesthetized mice and blood samples were taken from the retroorbital venous plexus. At approximately one half-life, 15 minutes, the gallbladder was retrieved. The concentration of SK in the gallbladder was determined based on radioactivity recovered in the bile and the known specific radioactivity of the I2'SK preparation. A 150 molar ratio for SK:Pg was calculated, and "'I-Pg was incubated with either 12'I-SK from bile or in buffer, and 10 mmol/L lysine, for 2 hours at 37OC. The reaction was terminated with 50 pmol/DCl and samples were reduced in sample buffer with DTT/SDS.
These experiments were performed in triplicate. 12'I-SK was incubated at 1:l ratio with unlabeled Pg for 10 minutes at 22OC and injected into mice. This incubation period is sufficient to ensure complete conversion SK:Pg to SK:PI~.~.' Activator complexes were injected directly after formation. Samples were then recovered from bile and electrophoresed under nondenaturing conditions. Duplicate 1: 1 activator complexes were formed under the same conditions and incubated for 15 and 45 minutes at 37OC with a 100-fold excess of human a,-macroglobulin (a2M), and samples were subjected to both nondenaturing PAGE and SDS-PAGE. The a,M was added to remove plasmin from the '251-SK:Pm complex.20 As previously described, this procedure results in a,M-Pm and a free SK fragment of mol wt -42,000 so that its mobility can be compared with the "'I-SK fragment found in bile after injection of '251-SK:Pm.ii Pg rather than the SK was labeled for some studies.
Activation assays.
Clearance of 'z51-SK:Pm complexes.
RESULTS
Plasma elimination of SK and PEG-SK. Clearance of I2'I-SK a t doses ranging from 0.15 to 30 p g resulted in identical plasma half-lives of approximately 15 minutes (n = 24) (Fig 1) . This is in agreement with our previous studies,, ' and clearance closely follows first order kinetics. Clearance of PEG-2-1251-SK (n = 2) demonstrated a halflife of greater than 200 minutes (Fig 1) . SDS-PAGE showed that "'I-SK recovered from retroorbital venous plexus blood was not degraded (Fig 2) . Additionally, "'I-SK that was cleared by the liver was also undegraded and demonstrated the same mol wt as native I2'I-SK (Fig 3) . I2'I-SK that was present in bile was homogeneous and of the same mol wt as native SK (n = 4). Nondenaturing P A G E of I2'I-SK from blood, liver, or bile, and control 12'I-SK showed the same mobility (data not shown). The lack of degradation of PEG-"'I-SK in bile was also shown by SDS-PAGE (Fig 3) . Table 1 Competition studies showed only moderate increases in plasma half-lives when 100-to 5,000-
Competition studies.
For fold excesses of unlabeled to labeled ligand (0.15 pg) were coinjected (Fig 4) . Due to the significant renal component of S K clearance, nephrectomies were performed by ligating the kidneys in an attempt to define more clearly the competition effect (Fig 4) . While competitions with a 5,000-fold excess of unlabeled SK in nephrectomized animals prolonged halflives to some extent, 10,000-fold excess with nephrectomy showed no further competition (data not shown). This inability to saturate clearance pathways with plasminogen activators has been observed previously. 22 In one experiment, a b c '251-SK was coinjected with a 10,000-fold molar excess of unlabeled SK and a 160,000-fold molar of albumin simultaneously with no effect on clearance (data not shown).
------ Similarly, a 1,000-fold molar excess of human lactoferrin were not technically feasible because the volume of bile was failed to alter plasma elimination of "'I-SK (data not so small. shown).
Clearance of '251-SK:Pm activator complexes. Activator Binding to and activation of plasminogen by catabolized complexes formed by 1 : 1 stoichiometric incubation of I2'I-'"I-SK.
Bile containing the "'I-SK was also incubated SK and unlabeled Pg were injected at a dose range of 10 to 30 with Pg for 10 minutes at 22OC and then electrophoresed pg per animal, recovered from bile, and electrophoresed. The under nondenaturing conditions. Figure 5 illustrates the plasma half-life of these complexes was approximately 3 difference in migration of the "'1-SK:Pm complex formed minutes, with no evidence of dose-dependence consistent with bile-derived "'I-SK and native "'I-SK. This study with previous reports."." Electrophoresis of bile showed that shows that the "'I-SK which has been recovered from the the radioligand from the complex migrated at a position murine system retains the ability to complex with Pg.
higher on the nondenaturing gradient gel than either native Catalytic amounts of "'I-SK present in bile were then SK or SKPm (Fig 7) . There were two possible explanations incubated with '''I-Pg for 2 hours at 37OC in the presence of 10 mmol/L lysine. SDS-PAGE (Fig 6) showed activation of the "'I-PG. While activation of "'I-Pg by bile-derived "'I-SK is less extensive than the control, these studies suggest that the.recovered S K binds to Pg to produce an activator complex, which retains the ability to cleave Pg. Differences in activation between the control and bilederived "'I-SK may be due to incomplete recovery of "'I-SK bound to gallbladder tissue. Attempts were also made to assay the plasmin generated by use of the substrate S-2251. However, the absorbance of the bile precluded obtaining an accurate end point. Attempts to purify bile-derived "'I-SK z o l " " For personal use only. on November 10, 2017. by guest www.bloodjournal.org From for this altered mobility: (1) the '2SI-SK was still present in some form of complex with plasmin; and (2) the band represented a cleavage product of SK with altered charge. Previous studies showed that murine catabolism of SK:Pm involves transfer of the plasmin moiety to a 2 M with the SK undergoing catabolism by a distinct mechanism.'z*20.2' No evidence exists for formation of a stable ternary intermediate with either murine or human a2M.20*21 While these studies were most consistent with the second hypothesis, it was decided to experimentally examine this question. Because incubation of "'1-SK:Pm complexes with a 2 M removes the plasmin, this treatment can be used to obtain the S K moiety of the complex.'2.20.2' Incubation of the SK:Pm complex results in time-dependent cleavage of the SK to a fragment of mol wt -42,000.12. '5.20.21 Therefore, in control experiments, a,M was incubated with I2'I-SK:Pm and the preparation electrophoresed in nondenaturing PAGE. The migration of the I2'I-SK:Pm preparation obtained from bile was compared (Fig 8) . As can be seen, the I2'I-SK in all cases showed the same mobility. In another series of experiments, SK:I2'I-Pm was injected into mice. These studies clearly indicated that plasmin and SK undergo separate catabolism, since only 4% as much "'1-plasmin was found in the gallbladder as "'I-SK when comparable amounts of SK:Pm were injected with SK or plasmin radiolabeled, respectively. Finally, clearance of PEG-I2'I-SK:Pm was studied. PEG-'"I-SK:Pm activator complexes cleared slowly from circulation with approximately 50% of the material remaining in circulation at 60 minutes (data not shown). The majority of the radioactivity was recovered in the gastrointestinal (GI) tract and liver (Table 1) . These studies are consistent with our prior observations,I2 although autopsy data were not previously reported. However, the fate of S K in these complexes has not been studied in detail.
When S K is infused into patients at therapeutic levels, a,-antiplasmin is the initial inhibitor of the resultant plasmin. However, this inhibitor is rapidly depleted because of its low concentration in plasma, and subsequently a,M is the major antipla~min.'~'~ Similar results are observed in the murine model." The catabolism of plasmin in complex with S K has been studied in vivo in the mouse mode1'2.2' and in vitro in murine and human pla~ma.~"' In human plasma, the plasmin is transferred preferentially to a,-antipIa~min,~' while in murine plasma the plasmin is preferentially transferred to a2M21*30 with release of free S K observed in both case^.^^.^' However, human a,M in the absence of a,-antiplasmin is a potent inhibitor of SK:Pm, and detailed analysis of this reaction confirms the transfer of plasmin to a,M with release of SK in a degraded form of mol wt -42,000.20 Thus, under therapeutic conditions in humans where a,-antiplasmin is depleted, SK:Pm catabolism should involve an interaction with a , M .
For these reasons, the murine model is an appropriate one for study of SK:Pm catabolism, despite the fact that murine a,-antiplasmin is not involved in catabolism of SK:Pm complexes in this species. Moreover. since murine Pg does not react with SK,' the model allows for the comparison of the catabolism of native SK and the mol wt -42,000 degradation product of SK obtained after SK reacts with Using the murine model, we now observe that both SK and its mol wt -42,000 fragment are secreted intact from the liver into the bile. Moreover, native SK retains its ability to complex and activate Pg. PEG-SK catabolism was shown to involve a similar mechanism. This observation is important for two reasons. First, the derivatization of SK lysine residues by PEG prevents degradation of SK so that the mol wt -42,000 fragment is not produced." Second. Beckman et aI3' have shown that coupling of PEG to superoxide dismutase favors endothelial uptake of the conjugate. Hence, PEG-SK may have shown a significantly different catabolic pattern.
It is somewhat surprising that a protein of bacterial origin such as S K should be secreted by liver in an intact form. Hepatic uptake and transport pathways for a number of mammalian proteins such as albumin, immunoglobulin A (IgA), transferrin, lactoferrin, and asialoglycoproteins have been studied in
In the present studies, we examined the possibility that some of these pathways might be involved in SK catabolism. The competition studies performed do not suggest that bulk phase transport3' or the metalloprotein clearance pathway^^^.'^.^^^^' are involved in the catabolism. It is important to note that nondenaturing PAGE of "'I-SK cleared and recovered in bile showed no change in migration compared with native '2'l-SK. Thus, an association with a carrier protein is not evident nor is the acquisition of a secretory component common to receptor-mediated hepatic transport of IgA ~u g g e s t e d .~~.~ Circulatory proteins found in bile have a variety of potential pathways for transport. They may take transcellular routes across the hepatocyte resulting in direct fusion with the bile caniculus, or initially be subject to lysosomal degradation and then be deposited in bile via the bile caniculus. They may follow a paracellular route with or without nonparachymal cell mediation. Additionally, biliary proteins may diffuse laterally across the hepatocyte plasma membrane after insertion into the sinusoid or may be transported from periductal epithelia." A range of proteins using these various pathways have been studied as noted abo~e.~"'"' Hydrolytic enzymes of the lysosome are likely to preclude it as an intermediate vesicle during biliary transport of SK considering the intact and functional state of S K in bile. Direct transcellular transport and exocytosis into the bile caniculus, initiated by hepatocyte surface endocytosis, is one plausible route for SK transport. However, the possibility of insertion into the sinusoidal domain of the hepatocyte plasma membrane followed by lateral diffusion to the canicuIus cannot be excluded by our results.
In summary, we have shown that intact and functional SK is secreted by the liver into bile. Although clearing at a slower rate, PEG-SK appears to be removed by the same mechanism. The latter observation is important in view of the potential role of PEG-SK as a fibrinolytic agent.
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